ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

ClinicalTrials.gov ID: NCT03742895

Public ClinicalTrials.gov record NCT03742895. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 3:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Study identification

NCT ID
NCT03742895
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
326 participants

Conditions and interventions

Interventions

  • Olaparib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 11, 2018
Primary completion
Aug 11, 2025
Completion
Jun 29, 2026
Last update posted
Feb 17, 2026

2018 – 2026

United States locations

U.S. sites
24
U.S. states
16
U.S. cities
20
Facility City State ZIP Site status
The University of Arizona Cancer Center - North Campus ( Site 0011) Tucson Arizona 85719
St Joseph Heritage Healthcare-Oncology ( Site 0056) Fullerton California 92835
Cedars Sinai Medical Center ( Site 0002) Los Angeles California 90048
UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0007) San Francisco California 94158
Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0092) Aurora Colorado 80045
Winship Cancer Institute of Emory University ( Site 0025) Atlanta Georgia 30322-1013
Augusta University ( Site 0028) Augusta Georgia 30912
Markey Cancer Center ( Site 0018) Lexington Kentucky 40536
University of Maryland ( Site 0050) Baltimore Maryland 21201
Weinberg Cancer Institute at Franklin Square ( Site 0054) Baltimore Maryland 21237
University of Massachusetts ( Site 0017) Worcester Massachusetts 01655
Henry Ford Health System ( Site 0060) Detroit Michigan 48202
Cancer Partners of Nebraska ( Site 0051) Lincoln Nebraska 68510
Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0116) Middletown New Jersey 07748
Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 0126) Harrison New York 10604
VA New York Harbor Healthcare System Manhattan ( Site 0094) New York New York 10010
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0057) New York New York 10016
Memorial Sloan Kettering Cancer Center ( Site 0026) New York New York 10065
Southwestern Regional Medical Center, Inc. ( Site 0079) Tulsa Oklahoma 74133
Eastern Regional Medical Center, Inc. ( Site 0077) Philadelphia Pennsylvania 19124
Sanford Hematology Oncology-Sioux Falls SD ( Site 0012) Sioux Falls South Dakota 57104
Intermountain Healthcare ( Site 0043) St. George Utah 84790
Virginia Mason Medical Center ( Site 0052) Seattle Washington 98101
Veterans Affairs Puget Sound Health Care System [Seattle, WA] ( Site 0093) Seattle Washington 98108

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 106 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03742895, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 17, 2026 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03742895 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →